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5 Introduction and Aims 
 
Joint disorders are frequently occurring problems involving cartilage as well as muscles, 
tendons, and ligaments, rather than bones; and often cause significant pain and 
dysfunction. Non-operative medical treatment is aimed to reduce pain and inflammation 
and include pharmacological approaches such as corticosteroids and non-steroidal anti-
inflammatory drugs (NSAIDs). Due to negative side effects of such medication, 
permanent treatment is not recommendable. Non-pharmacological approaches such as 
lifestyle changes including a healthy diet may be an alternative way to reduce symptoms 
and slow down progression of joint diseases. 
The main objective of the present diploma thesis was to evaluate and critically examine 
essential associations between selected nutritional components and their impact on joint 
disorders. The first part of the work outlines the role of selected nutritional compounds 
and  their  possible  influences  on  joint  disorders.  The  protocol  of  a  critical  review  
focusing on potential effects of omega-3 fatty acids (n-3 FAs) in shoulder disorders 
including osteoarthritis (OA) and rotator cuff (RC) pathologies is integrated as second 
part of the diploma thesis. 
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6 The joint 
 
The first part of this diploma thesis is an introduction into the joint anatomy and 
physiology as well as an explanation of selected, nutrition-related joint disorders and 
possible influences of special nutrients on pathogenesis.  
 
6.1 Anatomy and physiology of the joint 
 
The  part  where  two  or  more  bones  are  joined  to  each  other  is  described  as  joint  or  
articulation [GRAY 1918]. Such constructs not only provide mechanical support, but 
also allow movements. Joints are therefore either classified according to their functions, 
which are determined by the degree of movement between the articulating bones, or to 
their structures, which are differentiated in how the bones connect to each other.  
 
The three functional classifications of joints are 
 
1. synarthrosis (immovable joints)  
The surfaces of the bones are almost in direct contact. The joint space is filled 
with  connective  tissue  or  hyaline  cartilage.  The  bones  of  the  scull,  except  the  
mandible, are examples for this type of joint.  
 
2. amphiarthrosis (slightly movable joints)  
This type of joint is composed of joint space, capsule, synovia and special types 
of ligaments. Because of the strength of the ligament-bonding, movement is 
limited, which is the only difference to diarthrosis. An example for this kind of 
joint is the connection between pelvis and spine.  
 
3. diarthrosis (free movable joints)  
The main part of joints refers to this class. The parts of the joint are the same as 
explained above – joint space, capsule, synovia, and ligaments, but ligament-
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bonding is less strong, therefore free movement is possible. Examples for 
diarthrosis are the shoulder joint or the knee joint.  
[ROHEN and LUTJEN-DRECOLL 2006, GRAY 1918] 
 
In the following only the diarthrosis will be described, because this group of joints is 
affected by joint diseases relevant for this work. 
 
The free movable joints, the diarthrosis, can be structured into three subgroups: 
 
1. joints with one degree of freedom 
Motion in one plane is possible, which is either a forward and backward motion 
or a limited rotation. Both types are parts of the elbow joint. 
 
2. joints with two degrees of freedom 
This type of joint allows motion in two levels, bending and rotation axes. An 
example is the knee joint. 
 
3. articulations with three degrees of freedom 
Motion in all dimensions is possible. Shoulder and hip are joints with three 
degrees of freedom. 
[ROHEN and LUTJEN-DRECOLL 2006] 
 
The three structural classifications of joints include 
 
1. fibrous joints 
The bones are connected to each other with tissue rich in collagen fibers. 
2. cartilaginous joints 
The bones are joined by cartilage. 
3. synovial joints 
The bones are not directly connected to each other. [IQBAL 2012] 
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In general the basic structure of a joint is always the same (Figure 1). It is composed of 
the joint bodies, whose articular surfaces are coated in hyaline cartilage-tissue, and the 
articular capsule. The synovial membrane is the inner coat of the joint capsule. 
Additionally, the joint is passive stabilized by strong ligaments. Muscles and tendons 
are  responsible  for  active  and  dynamic  stabilization  as  well  as  for  motion  of  the  
articulation. The space between two joint bodies, the joint space, is filled with synovial 
fluid. The hyaline cartilage is made of matrix-tissue and chondrocytes. [NIETHARD 
and PFEIL 2005] 
 
Figure 1: A typical joint structure 
[modified according to NIETHARD and PFEIL 2005] 
 
During childhood and adolescence chondrocytes are responsible for the cartilage growth 
and regeneration. Hormones, metabolites and enzymes are important factors in the 
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regulation of the cell growth. With higher age normal chondrocytes lose their mitotic 
activities and a regeneration of cartilage in case of degeneration is only possible by 
using  alternate  tissue  from spongy bones  or  synovial  tissue  of  the  border  areas  of  the  
cartilage. [NIETHARD and PFEIL 2005] 
 
As seen in Figure 2, the articular cartilage is divided into 4 zones with individual matrix 
regions. The cell-free superficial zone includes the gliding surface of the joint. A layer 
of elongated chondrocytes are organized parallel to the articular surface. The matrix 
shows fine fibrils with few polysaccharides, endoplasmic reticulum, Golgi membranes, 
and mitochondria but the cells of this area are almost inactive. The transitional zone is 
the second layer and contains active chondrocytes including endoplasmic reticulum, 
Golgi membranes, mitochondria, glycogen and intracytoplasmic filaments. Compared to 
the superficial zone, the fibrils of the transitional zone are larger and columnar 
organized. 
 
Figure 2: Composition of the joint cartilage 
[modified according to NIETHARD and PFEIL 2005] 
 
Third layer is the deep zone with chondrocytes quite similar to the transitional zone but 
with a different organization (perpendicular to the joint surface). 
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These cells contain large amounts of intermediate filaments, glycogen granules, large 
collagen fibrils and the highest amount of proteoglycans. An increasing number of 
proteoglycans  leads  to  a  decreasing  amount  of  water  from  the  superficial  zone  to  the  
deep zone.  
The deepest zone of cartilage is the border between softer cartilage and subchondral 
bone. The chondrocytes contain low amounts of cytoplasm and endoplasmic reticulum. 
[JAMES and UHL 2001] 
 
For an adequate supply of the joint with all necessary nutrients two delivery-systems are 
responsible. The systems are termed as subchondral and synovial drift.  
Subchondral drift is the supply with nutrients and oxygen of those parts of the joint, 
which are directly connected to the blood supply. [NIETHARD and PFEIL 2005] 
The hyaline cartilage itself is avascular. That means that the chondrocytes are not 
directly connected to the blood supply. Thus, the synovial fluid is responsible for 
nutrient transport into the cartilage-cells as well as for the evacuation of metabolic 
waste from the chondrocytes. This exchange of substances is induced by exposure of 
the joint. A- and B-cells of the synovial membrane produce hyaluronic acid, which are 
free or bonded to proteins, and proteins, which are parts of the synovial fluid. 
[NIETHARD and PFEIL 2005, DÖLL 2007] 
 
The detailed composition of the synovial fluid, as listed below, is similar to blood 
plasma. 
 
Composition of synovial fluid 
? approximately 94% water 
? sugar content of approximately 66 mg/100 ml 
? hyaluronic acid content of 2,5 - 2,7 g/l (consists of free hyaluronic acid chains or 
proteoglycan aggregates) Hyaluronic acid is highly hydrophilic, but it declines 
with ageing. Concentration of hyaluronic acid defines viscosity of the synovial 
fluid. 
? protein content of approximately 15-25 g/l (synoviocytes, monocytes, 
lymphocytes and granulocytes) [BERG 2003, TITTEL 2003] 
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Additional to the nutrition based function, the synovial fluid is also responsible for the 
lubrication  and  shock  absorbance  of  the  joint.  [NIETHARD  and  PFEIL  2005,  BERG  
2003, TITTEL 2003] 
Inflammation within the articulation results in composition changes of the synovial 
fluid, which leads to reduced lubrication and less slippage. [TITTEL 2003] 
 
 
 
6.2 Joint disorders 
 
Joints, especially the cartilage, can be damaged by many types of injuries or diseases, 
however cartilage destructions are either mechanically or biologically induced.  
Biological factors are nutritional disturbances within the cartilage (age-related or 
cytotoxic substances) but also enzymatic destruction by enzymes secreted by cells of the 
synovial membrane (e.g. leucocytes in case of joint-maturation). [NIETHARD and 
PFEIL 2005] 
Reasons for mechanical destruction are trauma, acute or chronic overstress and 
immobilization. [NIETHARD and PFEIL 2005] 
The following chapter describes only those joint disorders regarding etiology and 
clinical course, which may be related to or influenced by the daily diet. 
 
6.2.1 Osteoarthritis 
 
Degenerative joint disorder or osteoarthritis (OA) is primarily associated with the aging 
process. With the third decade of life degeneration of connective and supporting tissue 
is a normal process of aging, and at the age of 65 nearly everybody is affected, but with 
differences in medical condition. [NIETHARD and PFEIL 2005] 
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6.2.1.1 Pathogenesis 
 
OA is caused by an increasing breakdown and loss of cartilage in joints. Affected are 
weight-bearing joints, the vertebral column and peripheral and axial joints. The most 
affected peripheral joint is the knee followed by shoulder and hip. [NIETHARD and 
PFEIL 2005, BERKSON 1991] 
 
Causes for the incidence of OA are  
? physical overstress 
? traumata 
? inflammatory articulation-processes 
? metabolic disorders 
? endocrine disorders 
 
Physical overstress of the joint is always part of the pathogenesis of OA. This 
mechanical stress in the articulation leads to irritation, such as wear and inflammation. 
Severe wear leads to a greater degree of inflammation and this higher degree of 
inflammation leads to an increased amount of wear and cartilage degradation. 
[NIETHARD and PFEIL 2005, BERKSON 1991] 
 
Development of degenerative joint disorders is a slow progressive process. One of the 
first symptoms is the loss of elasticity with changes in the joint tissue such as decreased 
cartilage-thickness, fissure formation in the cartilage and subchondral scleroses. This 
damage of the articulation causes thrust and shear forces, which lead to a typical 
deformation of the joint. If the process of degeneration is accelerated, the symptoms of 
OA become clinical relevant.  
OA clinically appears with pain, swellings, muscle tension, limitation of motion and 
stiffness after prolonged periods of immobility and increasing joint deformation. 
[NIETHARD and PFEIL 2005, BERKSON 1991] 
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6.2.1.2 Therapy 
 
Prevention of the progression of degenerative joint disorder rand the reduction of pain, 
swelling and immobility are the most important treatment options, since there is no 
direct cure for OA. Obesity and physical inactivity are main risk factors for the 
incidence of OA and should also be considered in the therapy. Therefore, in acute 
phases immobilization and steroidal and non-steroidal antiphlogistic medication, later 
on remedial gymnastics and is recommended. In advanced stages of OA surgical 
intervention is recommended. [NIETHARD and PFEIL 2005] 
 
The focus of medical intervention to treat or reduce symptoms of OA as well as other 
joint disorder is to reduce pain and inflammation. In acute phases of diseases a medical 
intervention is necessary, because symptoms (pain, swelling, immobility) are too strong.  
 
In the following non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids 
and their mechanism of action will be explained.  
 
6.2.1.3 NSAIDs 
 
NSAIDs have analgesic and antipyretic and, in higher doses, anti-inflammatory effects. 
In  the  therapy  of  OA and rheumatoid  arthritis  NSAIDs is  one  of  the  most  commonly  
used drugs.  
Due to their selectivity NSAIDs can be classified into COX-2 selective or non-selective 
NSAIDs, non-aspirin or aspirin and salsalate drugs and acetaminophen [CHOU et al. 
2011] 
 
Mechanism of action 
 
NSAIDs decrease pain, inflammation, and fever by blocking cyclooxygenase (COX) 
enzymes. In particular NSAIDs affect the isoenzymes COX-1 and COX-2. COX-1 acts 
as a mediator in the gastrointestinal tract and protects the gastrointestinal mucosa from 
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acid and platelet aggregation. COX-2 mediates processes concerning inflammation and 
pain and is located throughout the body, including joints and muscles. NSAIDS reduce 
pain (occurring with OA or rheumatoid arthritis) by blocking COX-2.  
Permanent medical treatment with NSAIDS has to be taken with caution due to strong 
side effects. The drawback of so called non-selective NSAIDs is that both enzymes, 
COX-1 and COX-2, are being blocked. One of the most dreaded consequences is the 
destruction of the gastric mucosa caused by the blocking of COX-1. [CHOU et al. 2011] 
NSAIDs vary in their selectivity for COX-2 meaning how much they affect COX-2 
relative to COX-1. Thus, if they only block COX-2 but not COX-1, they are called 
COX-2 selective NSAIDs, they might reduce inflammation and pain without any 
negative side effects on the gastrointestinal tract. [CHOU et al. 2011] However, as 
explained above, NSAIDs are associated with several other negative effects. 
In addition to the side effects interactions between NSAIDs and other drugs, e.g. blood 
thinner, cardio-active drugs, diuretics, preparations against hypertension and anti-
depressants will occur. A parallel intake of NSAIDs and other drugs can either increase 
or lessen the effect of NSAIDs. [DÖLL 2007] 
 
6.2.1.4 Corticosteroids 
 
Corticosteroids (corticoids) are also often used to treat joint disorders. The best known 
member of this group is cortisone.  
 
Cortisone is a steroid hormone synthesized in the human body by the adrenal gland in 
response to stress. In extended periods of hunger glucocorticoids initiate the proteolysis 
and gluconeogenesis in the liver. Additionally cortisone suppresses the immune system 
and subsequently decreases inflammation, pain and swelling. [LÖFFLER 2004] 
In its function as immune suppressor, cortisone weakens the organism if taken over a 
long period of time. [LAXMAIAH MANCHIKANTI 2002] 
 
In  case  of  long-term,  high  dose  medical  treatment  with  steroid  hormones  such  as  
cortisone several negative side effects may occur. Examples are hyperglycemia, 
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immunosuppression, hypertension, precipitation of diabetes mellitus, osteopenia and 
osteoporosis, muscle and joint pain, psychological imbalances, gastrointestinal 
disturbances, as well as dermatological and metabolic problems. [LAXMAIAH 
MANCHIKANTI 2002] 
 
Due to the long list of possible side effects, an alternative to NSAIDs and 
corticosteroids could be of special interest. Therefore nutritional components are under 
discussion  to  be  such  an  alternative  or  an  additional  way to  treat  symptoms of  OA as  
well as other joint disorders. 
 
6.2.1.5 Dietary factors associated with osteoarthritis 
 
Obesity and metabolic syndrome 
 
As explained above OA is a disease where weight-bearing joints, such as knee and hip, 
are affected. Therefore obese people whose weight-bearing joints are under greater 
strain have a higher risk of developing OA. It has been reported that weight loss reduces 
pain,  and improves function for patients with OA who are obese or overweight.  [LEE 
and KEAN 2012, BROSSEAU et al. 2011] However, not only weight-bearing joints, 
but also other joints, such as the hand joint, are also affected in case of obesity or 
overweight. Responsible is a systemic effect including adipokines with pro-
inflammatory and degenerative effects, secreted by adipose tissue, as well as some joint 
cells.  [SELLAM and BEERENBAUM 2012]OA is  also  associated  with  the  metabolic  
syndrome including type-2 diabetes, a reason for cardiovascular mortality. Early-onset 
OA is suspected to be a reason for the incidence of the metabolic syndrome. [SELLAM 
and BEERENBAUM 2012] 
In  either  case  weight  loss  strategies  including  diet  and  physical  activity  are  
recommended to prevent OA and reduce related symptoms. [LEE and KEAN 2012, 
BROSSEAU et al. 2011, SELLAM and BEERENBAUM 2012] 
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Anti-inflammatory nutrients 
 
Not only obesity is a nutrition related risk factor to cause OA, inflammatory processes 
could be influenced by the diet as well. Antioxidants, vitamin D, chondroitin and 
glucosamine, polyunsaturated fatty acids (PUFAs) and phytochemicals are under 
discussion to have positive influence on the progress and intensity of arthritis. [AMEYE 
and CHEE 2006, MCALINCON and BIGGEE 2005] 
 
6.2.2 Inflammatory-rheumatic joint disorders 
 
Rheumatism is a hyponym for about 100 diseases with different clinical presentation, 
pathogenesis, etiology, localization, prognoses and characteristic. Therefore, a 
classification by localization and type is sensible. 
 
? inflammatory-rheumatic joint disorder with affection of one or several 
articulations 
? degenerative-rheumatic joint disorder 
? osteoarthritic disorders without inflammatory background  
? rheumatic soft-tissue disorder 
? degenerative and inflammatory disorders of muscles, tendons, ligaments and 
ligament sheaths [NIETHARD and PFEIL 2005] 
 
Rheumatoid arthritis 
 
According to the Austrian Medical Chamber approximately 0.4 - 1 % of adults in 
industrial countries are affected by rheumatoid arthritis [ÖAK, 2012], women three 
times more than men. [NIETHARD and PFEIL 2005, RHEUMA-ONLINE 2012] 
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6.2.2.1 Pathogenesis 
 
Typical for rheumatoid arthritis is the poly-articular involvement, symmetric allocation 
and chronicity. Pathogenesis is almost unknown. Most hypotheses emanate from 
hereditary disposition and environmental antigens, especially viruses and bacteria, as 
triggers of rheumatoid arthritis [NIETHARD and PFEIL 2005, IDELBERGER 1978, 
HAIKE 1974]. 
Additionally nutrition, mental stress and unknown environmental contaminants as 
influencing and interacting factors are under discussion. The immune system reacts with 
hyperactivity which leads to aggressive synovitis with degeneration of cartilage and 
joint. [NIETHARD and PFEIL 2005] 
 
In some cases blood serum of affected people shows specific antibodies, so called 
rheumatoid factors. Rheumatoid factors are predominantly anti-immunoglobulin G 
(anti-IgG) directed autoantibodies of the immunoglobulin M (IgM) class. However, at 
early-stage diseases not everyone with a rheumatoid factor found in the blood has a 
rheumatic disease. Later, in an advanced stage, about 80% of the affected patients show 
a  positive  rheumatoid  factor  test.  In  most  cases  a  significant  anemia  is  diagnosed.  
[NIETHARD and PFEIL 2005] 
 
First place of manifestation are joints of the hand or feet. Symmetric swellings of the 
metacarpophalangeal and interphalangeal joints often occurs at the beginning, followed 
by  the  articulations  of  knee,  shoulder,  hip,  elbow  and  the  ankle  joint.  In  other  cases,  
among younger people, rheumatoid arthritis can also start as an acute mono-arthritis, 
where the bigger joints, such as knee, elbow, shoulder, and the vertebral column are 
affected. [NIETHARD and PFEIL 2005, HAIKE 1974] 
 
6.2.2.2 Therapy 
 
Depending on stage and activity of the inflammatory changes of the disease, different 
treatments are necessary. Medical treatment with NSAIDs and cortisol is recommended 
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at  all  stages;  at  advanced  stages  with  strongly  affected  joints,  surgical  excision  of  the  
immunological active tissue is needed. Additional physiotherapy and exercise therapy is 
required. [NIETHARD and PFEIL 2005] 
 
6.2.2.3 Dietary factors associated with rheumatoid arthritis 
 
Dietary factors associated with rheumatoid arthritis are rather uncertain and not 
evidence based. Lahiri et al concluded that dietary antioxidants and breastfeeding may 
be protective, and high coffee consumption (more than four cups per day) may increase 
the risk to develop rheumatoid arthritis. An increased risk with obesity is also discussed. 
[LAHIRI et al 2012] 
In a review by Miles and Calder a moderate positive effect of marine n-3 FA on 
symptoms of rheumatoid arthritis such as duration of morning stiffness, pain and 
swelling in joints has been reported. Reasons are anti-inflammatory and immune-
modulating effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 
present in fish oil and fatty fish. Arachidonic acid (AA) is the precursor of inflammatory 
eicosanoids involved in rheumatoid arthritis. EPA and DHA decrease the production of 
inflammatory  eicosanoids  from  AA.  EPA  and  DHA  could  also  affect  other  immune  
related systems relevant in rheumatoid arthritis, such as dendritic cells, T cell function 
and production of inflammatory cytokines and reactive oxygen species. [MILES and 
CALDER 2012] 
 
The German Nutrition Society (DGE) published recently nutritional recommendations 
for inflammatory diseases especially for rheumatoid arthritis. Nutritional treatment of 
rheumatoid arthritis can be seen as an additional treatment to medication. A lacto-
vegetarian diet based on vegetables and fruits, low in fat milk products, low meat and 
fat intake and fish twice a week (at least on portion of fatty fish per week), could have 
positive impact, if practiced over a period of at least 3 month. [DGE 2008] 
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6.2.3 Metabolic Arthropathy – Articular Gout 
 
Gout is a metabolic disease which occurs in recurrent attacks. Due to the deposit of uric 
acid crystals in the peripheral joints and tissues, it leads to destruction of the joints. The 
onset of the disease is in middle age of life. Men are more affected than women. 
[NIETHARD and PFEIL 2005, DÖLL 2007] According to Mikuls et al., who analyzed 
the UK General Practice Research Database from 1990 to 1999 including approximately 
1.7 million patients (49 % men), the overall prevalence of gout is about 1.4%, the 
overall male to female ration is 3.6:1. Prevalence rises up to 7.3 % in men between 75 
and 84 years. [MIKULUS et al. 2005] 
 
6.2.3.1 Pathogenesis 
 
There are two types of gout classified. Primary gout is caused by a genetic defect 
concerning the purine metabolism. This disorder leads to a reduced renal excretion of 
uric acid as well as to an increased synthesis.  
Reasons for the incidence of the secondary gout are an increased synthesis or supply of 
uric acid and a decreased elimination of uric acid due to a kidney disorder.  
The high level of uric acid in blood plasma results in deposition of urate crystals in 
cartilage, capsule and tissue in joints of the toe, finger and elbow. [NIETHARD and 
PFEIL 2005, DÖLL 2007] 
 
6.2.3.2 Therapy 
 
Acute gout attacks necessitate medication to reduce pain, maintenance treatment to 
reduce the plasma level of uric acid with dietary measures and medication to increase 
excretion  and  reduce  synthesis  [NIETHARD and PFEIL 2005].  NSAIDs are  the  most  
common drugs used in the treatment of gout and oral corticosteroids are a possible 
alternative. [RICHETTE and BARDIN 2010] 
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6.2.3.3 Dietary factors associated with gout 
 
Acute gout attacks require medical treatment, but modifiable risk factors such as diets 
high in purine, high alcohol consumption, overweight, diabetes and hypertension should 
be addressed. [EGGEBEEN 2007, HAYMAN and MARCASON 2009]  
Huang et al. investigated the effects of Vitamin C supplementation on serum 
concentrations of uric acid in a RCT involving 184 hyperuricemic patients. In this study 
Vitamin C supplementation (500 mg/d, duration of 2 month) reduced serum uric acid 
concentration statistically significant (mean change of - 0.5 mg/dl). [HUANG et al. 
2005] 
 
 
6.3 Muscles and tendons as part of the joint 
 
In the following anatomy and physiology of muscles and tendons are described, because 
of their importance in maintaining joint stability and movement. 
 
6.3.1 Anatomy and physiology of muscles and tendons 
 
As seen in Figure 3 the skeletal muscle consists of bundles of muscles, which, 
themselves, are comprised of various numbers of muscle fibers or muscle cells. The 
main parts of the muscle cell are so called myofibrils with the contractile protein 
components actin and myosin. The sarcomere is the smallest unit of the myofibril. It 
consists of thin layers of active actin filaments (I-Band) and actin and myosin filaments 
next to each other (A-Band), connected to the Z-disc, and thicker myosin filaments (H-
Band). Several muscle fibers are innervated by one single nerve, the so called motor 
neuron. Nerve and muscle fiber form the motor unit (M). This M is in the focus of the 
muscle contraction.  
The contraction of the muscle can be isotonic, isometric, auxotonic or isokinetic. In case 
of  isotonic  contraction  the  myofibrils  generate  a  tension  and  get  shorter.  The  actin  
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filament glides over the myosin filament and the H-zone gets narrower. Contraction 
requires energy as adenosine triphosphate (ATP), and calcium is released from the cells. 
In relaxation periods actin and myosin returns in off-position and the muscle reverts to 
the initial situation. [NIETHARD and PFEIL 2005, HOHMANN et al. 2003] 
 
 
Figure 3: Anatomy of the muscle 
[modified according to NIETHARD and PFEIL 2005] 
 
Tendons and ligaments vary in their structural composition because of their different 
functions. Due to the fact that they work by tension, they are typically made of tight, 
parallel arranged connective tissue with spindle-shaped cells, the tendocytes. 
[NIETHARD and PFEIL 2005] 
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According to Niethard and Pfeil the components of the connective tissue are  
? collagen 
? proteoglycan 
? glycoprotein 
? elastin 
 
Collagen fibrils ensure tensile strength, elastic fibers act as damper. In case of loss of 
elasticity there is an increased risk for rupture. The tendon is covered in loose 
connective tissue, the so-called tendon sheath. In case of overstress inflammation could 
be a consequence. In the transitional area, as seen in Figure 4, where the tendon is 
connected to the bone (tendon-insertion), chondrocytes are enclosed to the tendon tissue 
to compensate the tension. [NIETHARD and PFEIL 2005] 
 
 
Figure 4: Tendon-bone insertion 
[modified according to NIETHARD and PFEIL 2005] 
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6.3.2 Muscle diseases 
 
In the following chapter only those muscles disorders were selected and described 
regarding their etiology and clinical course, which may be related to or influenced by 
nutritional components. 
 
6.3.2.1 Muscle inflammation 
6.3.2.1.1 Pathogenesis 
 
Causes for the incidence of myositis are bacterial, viral or parasitical. A bacterial 
induced inflammation as a consequence of injections into the muscle is the most 
common cause for myositis. Lymphocytic myositis is also possible in patients with 
inflammatory-rheumatic disorders.  
In aging people a special form of myositis, polymyalgia rheumatic, is a frequent 
occurring disorder. The joints of shoulder and hip are most commonly affected. 
[NIETHARD and PFEIL 2005] 
 
The only symptom of myositis is unspecific muscle pain, and in the case of polymyalgia 
rheumatica symptoms are shoulder and hip joint pain and an extremely disturbance of 
the general condition. [NIETHARD and PFEIL 2005] 
 
6.3.2.1.2 Therapy 
 
Abscesses as consequences of injections require surgical excision. Medical treatment 
with corticosteroids is the recommended intervention for polymyalgia rheumatica. 
[NIETHARD and PFEIL 2005] 
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6.3.2.2 Tendovaginitis 
 
Tendovaginitis is an inflammatory disorder of the tendon sheath. 
 
6.3.2.2.1 Pathogenesis 
 
Mechanical irritation and physical over stress lead to swelling of tissue and tendon 
sheath. In few cases, bacterial infections and rheumatic inflammations are causes for the 
incidence of tendovaginitis. Extraction of fibrin into the tendon sheath is the reason for 
the typical creaking of sliding fabric. [NIETHARD and PFEIL 2005] 
 
6.3.2.2.2 Symptoms 
 
In most cases tendovaginitis affects the joints of the hand. Symptoms are swelling, acute 
pain and pain in motion after unique or chronic physical overstress. [NIETHARD and 
PFEIL 2005] 
 
6.3.2.2.3 Therapy 
 
Immobilization and injections into the affected tissue with corticoids are common ways 
to treat tendovaginitis. [NIETHARD and PFEIL 2005] 
 
6.3.2.2.4 Dietary factors associated with myositis and tendovaginitis 
 
To best of our knowledge, there are no scientific studies approaching effects of dietary 
intervention on myositis and tendovaginitis. However, as myositis and tendovaginitis 
are inflammatory diseases, the anti-inflammatory effects of n-3 FAs (EPA and DHA in 
fatty  fish  or  fish  oil)  could  be  of  interest  to  reduce  pharmacologic  treatment.  n-3  FAs 
show anti-inflammatory activity by inhibiting membrane AA metabolism, and at the 
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same time synthesizes of pro-inflammatory prostaglandins from AA is reduced. 
[BRIEN 2008, WANN 2010, EFTHIMIOU and KUKAR 2010] 
 
6.3.2.3 Degenerative disorder of tendon, meniscus and bursa 
 
Tendons and menisci work by tension. In cases of strong physical strain degenerative 
changes are possible. Most affected areas are spinea and hip. The main symptom is 
pain. Disorders of bursa are inflammations with swelling and consequently associated 
pain. Inflammations in deeper tissue regions such as in the shoulder or hip often remain 
undetected. 
Degenerative disorders of tendon, meniscus or bursa require immobilization of the 
affected region. In some cases, if the inflammation is chronic, medical treatment with 
corticosteroids is recommended. [NIETHARD and PFEIL 2005] 
 
6.3.2.3.1 Dietary factors associated with degenerative disorders of tendon, 
meniscus and bursa 
 
From the scientific point of view, there are no nutritional recommendations concerning 
degenerative disorders of tendons, meniscus or bursa. In case of chronic inflammation, 
an additional treatment with anti-inflammatory nutritional compounds could be taken 
into consideration, to reduce corticosteroid or NSAID intake. n-3 FAs could be of 
interest, due to their important role in the initiation and regulation of inflammatory 
mediators. [GOLDBERG and KATZ 2007] 
  
28 
 
7 The shoulder joint 
 
As the shoulder will be in the focus of the following critical review, the following 
chapter will described selected shoulder pathologies and the effects of nutritional 
components on shoulder diseases will be discussed. 
 
7.1 Shoulder Joint 
 
The shoulder joint (Figure 8) has the greatest mobility compared to other joints in the 
human body. It permits the arm to be rotated, elevated, and extended both forward and 
backward. This flexibility is also the reason why the shoulder joint is an extremely 
unstable joint, thus has the greatest predisposition to injuries. 
 
7.1.1 Anatomy 
 
The shoulder joint assembles the following diarthrodial joints: 
? the glenohumeral joint 
? the acromioclavicular joint 
? the sternoclavicular joint 
? and the layer between scapula and posterior chest wall (scapulothoracic 
articulation).  
 
Shoulder joint bones are covered by articular cartilage and surrounded by fibrous 
articular capsules.  
A total of 80 % of all shoulder disorders are changes in the soft tissue. Problems 
concerning the rotator cuff (RC) are the most common reasons for pain in the region of 
the shoulder. [PLATZER 2005, NIETHARD and PFEIL 2005] 
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Figure 5: The shoulder joint 
[modified according to PLATZER 2005] 
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7.1.2 Rotator cuff muscles 
 
The RC (Figure 9) is a group of muscles and related tendons in the shoulder of the 
human body. Functions are stabilization and movement of the shoulder. The RC 
consists of 4 muscles, named supraspinatus, infraspinatus, teres minor and 
subscapularis. These muscles have their source at the scapula and connect to the head of 
the  humerus,  forming  a  cuff  at  the  shoulder  joint.  On  the  one  hand  this  construction  
ensures a high degree of mobility; on the other hand this dynamic stabilization involves 
a potential instability of the shoulder which often leads to luxation. [PLATZER 2005, 
NIETHARD and PFEIL 2005] 
 
 
 
Figure 6: The rotator cuff 
[modified according to NIETHARD and PFEIL 2005] 
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7.2 Shoulder pathologies 
 
As explained above, the shoulder is a very flexible joint and therefore prone to injuries. 
In the following chapter selected shoulder disorders and will be explained. At the end of 
this chapter the nutritional influences on shoulder disorders will be discussed. 
 
7.2.1 Shoulder instability 
 
Shoulder instability or dislocations of the shoulder can be classified into three groups: 
 
? habitual dislocation without traumatic background  
? arbitrary dislocation of the shoulder where patients are able to dislocate the 
shoulder whenever they want to 
? post traumatic recurrent habitual dislocation after traumatic dislocation 
[NIETHARD and PFEIL 2005] 
 
A constant feeling of instability within the shoulder is a typical clinical sign. Mobility is 
restricted leading to limitations at work and leisure time. Possible complications and 
long-term  consequences  are  chronic  shoulder  instability  or  OA  of  the  shoulder.  
[NIETHARD and PFEIL 2005, MILLETT et al. 2008] 
Surgical intervention is recommended in the treatment of recurrent shoulder dislocation. 
[NIETHARD and PFEIL 2005] 
 
7.2.2 Osteoarthritis of the shoulder 
 
Shoulder OA is a gradual, progressive, mechanical, and biochemical degeneration of the 
articular cartilage, bone and joint capsule of the shoulder. 
As a conclusion of wear of the cartilage surface, friction within the joint increases 
which leads to pain and disability. Risk factors for shoulder OA, or also known as 
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degenerative joint diseases of the shoulder, are various including age, genetics, gender, 
weight, joint infection, previous shoulder dislocation or injury. Physical overstress of 
the shoulder, such as overhead sports is a further risk factor. [MILLETT et al. 2008]  
 
The  main  objective  in  the  treatment  of  OA  is  to  lower  pain  and  restore  function.  
Therefore  medication  with  NSAIDs  and  corticosteroids  is  recommended.  Due  to  the  
numerous side effects (as explained in chapter 6.2.1.3. - 4) alternatives are of high 
interest. In some cases, if conservative therapies fail, surgical intervention is necessary. 
Non-surgical and non-pharmacologic intervention such as physiotherapy and exercise 
are unproven in the treatment of shoulder OA. [MILLETT et al. 2008] 
 
7.2.2.1 Dietary factors associated with the shoulder joint (cartilage) 
 
Shoulder dislocation is a disorder where nutritional intervention is not applicable. But as 
explained above, chronic shoulder instability could lead to shoulder osteoarthritis 
[MILLETT et  al.  2008].  The  main  nutritional  components  in  the  treatment  of  OA are  
glucosamine and chondroitin. However, at the moment a general recommendation for 
the use of glucosamine and chondroitin is not possible, since heterogeneity among 
glucosamine and chondroitin sulfate trials is high [RICHMOND et al. 2009, BRUYERE 
et al. 2008, VLAD et al. 2007]. As inflammation of the synovial membrane is a 
symptom  of  osteoarthritis  [KAPOOR  et  al.  2011]  treatment  with  anti-inflammatory  
nutrients such as n-3 PUFAs should be taken into consideration.  
 
7.2.3 Rotator cuff pathologies 
 
RC tears are ruptures of the tendons related to the four muscles supraspinatus, 
infraspinatus, subscapularis and teres minor. Traumata or degeneration of the tendons 
are reasons for the occurrence of tears. But a traumatic rupture without previous 
degeneration is rather infrequent.  
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Tears range from small partial tears to full thickness tears. Acute traumatic tears are 
painful but pain decreases over time. In case of degeneration of the RC over a long 
period, symptoms are rather mild. Pain is much more in focus than function restriction. 
Degenerative RC tears are very present in elderly with a prevalence of about 30%. 
[NIETHARD and PFEIL 2005] 
 
In the therapy pain and limited function are decisive factors. Among young patients 
with extensive clinical symptoms surgical intervention is recommended. [NIETHARD 
and PFEIL 2005] For painful partial RC tears NSAIDs and injections of corticosteroids 
in combination with supervised exercise should be considered. [ROBB et al. 2009] 
 
7.2.3.1 Dietary factors associated with the shoulder joint (tendons) 
 
There is a lack of scientific studies regarding tendon-related joint disorders and dietary 
supplementation [LEWIS and SANDFORD 2009]. However, nutritional alternatives to 
NSAIDs and corticosteroids could be of interest in the treatment of tendon and muscle 
related  shoulder  disorders.  Reduction  of  inflammation  processes  with  n-3  PUFA  
supplementation is even of high interest in chronic shoulder disorders. Treatment with 
proteoglycans as natural components of the soft tissue of the shoulder (tendons and 
muscles of the RC) could also be of interest.  
 
 
 
8 Diet and joint disorders 
 
In this chapter a selection of frequently discussed nutrients related to joint disorders are 
explained and the clinical relevance is evaluated. Table 1 gives an overview of the 
reviewed nutrients and studies.  
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Substance Reference Design Population Dosage/Parameter 
Duration 
Results 
Glucosamine 
sulfate 
Towheed et al.  Review 2570 500 or 1500 mg/day 
3 weeks–3 years 
significant improvement in pain and joint 
function 
 Reginster et al.  Review 624 1500 mg/d 
6–36 month 
significant improvement in pain and joint 
function 
 Wandel et al. 2010 Meta-analyses 3803 800-1500 mg/day 
1–156 weeks 
no clinical relevant effect on joint pain 
and joint space narrowing 
 Lee et al. 2010 Meta-analyses 414 1500 mg/day 
up to 3 years 
a small to moderate protective effect on 
minimum joint space narrowing 
 Vlad et al. 2007 Review 2613 1500 mg/day 
1 month–3 years9 
no significant outcome 
Chondroitin 
sulfate 
Hochberg 2010 Meta-analyses 1179 800-1200 mg/day 
2 years 
significant effect of slowing the rate of 
joint space narrowing 
 Reichenbach et al. 2007 Meta-analyses 3846 800–1200 mg/d (1x 200 mg/d 
1-32 weeks 
minimal or nonexistent symptomatic 
benefit 
 Lee et al. 2010 Meta-analyses 1088 800mg/day 
up to 2 years 
small but significant protective effect on 
minimum joint space narrowing 
Collagen 
hydrolysate 
Benito-Ruiz 2009 RCT 250 10 g/day 
6 month 
improvement of knee joint comfort 
 Bruyere et al. 2012 RCT 200 1200 mg/d 
6 month 
significant improvement in pain 
 Zuckley et al. 2004 RCT 190 10 g/day with calcium 
(300 mg/day) and 
vitamin C (60 mg/day) 
14 weeks 
improvement of knee functional mobility 
Vitamin D Bergink et al. 2009 Cohort 1248 serum level of  
25-hydroxyvitamin D 
low levels of vitamin D intake are related 
to an 
increased risk of OA progression 
 Brejawi et al. 2009 Cross-section 117 serum level of  
25-hydroxyvitamin D 
high prevalence of low vitamin D status in 
patients with knee OA 
 Felson et al. 2007 Cohort 993 serum level of  
25-hydroxyvitamin D 
no association between vitamin D 
levels and joint structure 
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Substance Reference Design Population Dosage/Parameter 
Duration 
Results 
AO Canter et al. 2007 Review 460 150-200 mg/day Selenium 
400-1200 mg/day Vit E 
3 weeks-12 month 
no significant outcomes for Vit A, C and 
Selenium, contradictory outcomes for 
Vit E 
 Brien et al. 2008 Review 681 DMSO topical 
MSM topical or orally 4-20 
g/day 
3-4 weeks 
significant improvement in pain 
Rosehip 
powder 
Christensen et al. 2008 Meta analyses 287 5 g/day or more (pain related – 
patients decision)  
3 month 
clinically relevant reduction of pain 
 Chrubasik et al. 2008 
 
One-year-Survey 296 5 g/day or more (pain related – 
patients decision) 
1 year 
improvement in pain 
ASU Henrotin et al. 2011 Review 435 300-600 mg/day 
3 month-2 years 
reduced progression of joint space loss, 
decreased NSAID and analgesic intake, 
beneficial effects on pain and joint 
function 
 Christensen et al. 2008 Meta analyses 664 300 mg/day 
3-12 month 
neither worse nor better than other 
medications for treating OA in knee and 
hip 
n-3 FA Brien et al. 2008 Review 402 630-5750 mg mussel extract/day 
or capsules of green lipped 
mussel extract(dose not 
reported) 
2-6 month 
improvement in pain and joint function 
 Dawczynski et al. 2011 RCT 60 3 g n-3 PUFA or 3.2 g GLA or 
1.6 g PUFA + 1.8 g GLA/day 
12 month 
n-3 PUFA and GLA increased EPA and 
DHA in plasma lipid cells 
 Adam et al. 2003 RCT 68 diet low in AA and fish oil 
capsules (30 mg/kg body 
weight/day) 
8 month 
significant improvement in tender and 
swollen joints, increased EPA an 
erythrocyte lipids, lower formation of 
prostaglandin metabolites 
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Substance Reference Design Population Dosage/Parameter 
Duration 
Results 
n-3 FA Galarraga et al. 2008 RCT 97 10 g cod liver/day (2.2 g EPA 
and DHA) 
9 month 
reduced NSAID intake  
 Berbert et al. 2005 RCT 34 3 g fish oil n-3 FAs improvement in joint pain intensity, 
handgrip strength, duration of morning 
stiffness 
 Stammers et al. 1992 in 
Henrotin et al. 2011 
 
 
Cho et al. 2003 in 
Henrotin et al. in 2011 
 
double-blind 
placebo-controlled 
trial 
 
multicenter open 
trial 
86 
 
 
 
60 
 
10 ml cod liver/day (786 mg 
EPA) 
24 weeks 
 
4 capsules of  
green lipped-mussel (200 mg 
extract) 
8 weeks 
no effect on pain and ability 
 
 
 
improvement of OA signs and symptoms 
(joint pain and function) 
 Goldberg and Katz 2007 Meta analyses 823 1,7-9,6 g n-3 FAs/day (fish oil 
or capsules) 
1-12 month 
reduced joint pain intensity, morning 
stiffness, number of painful and/or tender 
joints, and NSAID consumption 
 
Table 1: Summery of the reviewed studies concerning nutrients relevant in the treatment of joint disorders 
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8.1 Cellular components of the connective and 
supporting tissue 
 
Relevant  cellular  components  of  the  connective  and  supporting  tissue  of  the  joint  are  
glucosamine (glucosamine sulfate), chondroitin (chondroitin sulfate) and collagen 
(collagen hydrolysate).  
 
8.1.1 Glucosamine sulfate 
 
From a chemical point of view, glucosamine is a monosaccharide with an amino group 
instead of the hydroxyl group at the second carbon-position (C-2 position). This amino 
sugar is an important precursor in the biochemical synthesis of glycosaminoglycan, 
which are the side chains of proteoglycans. Therefore, glucosamine is an essential part 
of the extracellular matrix including ligaments, tendons, cartilage and synovial fluid. 
[THE AMERICAL HERITAGE® SCIENCE DICTIONARY 2005] 
 
D-fructose-6-phosphate and the amino acid L-glutamine are the precursors in synthesize 
of glucosamine in human organism.  
Dietary supplements are, in most cases, produced by hydrolysis of crustacean 
exoskeletons or fermentation of vegetarian sources. The precursor is chitin, which is a 
common nitrogenous polysaccharide in animal and funguses. [THE AMERICAL 
HERITAGE® SCIENCE DICTIONARY 2005] In 2006 Hathcock and Shao evaluated 
food safety of glucosamine sulfate. Based on the included clinical trials an upper save 
level for supplements (USL) of 2000 mg/d has been determined. There was no 
toxicological basis to determine whether a no observed adverse effect level (NOAEL) 
nor  a  lowest  observe  adverse  effect  level  (LOAEL).  [HATHCOCK  and  SHAO  2006]  
Glucosamine sulfate is approved as a pharmaceutical product in Austria with a daily 
dose of 1250 mg glucosamine. Products with lower amounts of glucosamine are 
available as dietary supplements. [BUNDESMINISTERIUM FÜR GESUNDHEIT 
2009] In the USA glucosamine sulfate is classified as a dietary supplement and is 
available over the counter. [VLAD et al. 2007] In the United Kingdom only one of the 
glucosamine products is licensed and available as a “prescription only medicine”. In 
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Europe most of the products are sold as dietary supplements and available over the 
counter.  [BLACK  et  al.  2009]  According  to  Reginster  et  al.  a  daily  oral  dose  of  
1500 mg glucosamine sulfate per day is effective and safe, and used in most of the 
existent trials concerning glucosamine sulfate. [REGINSTER et al. 2012]  
 
In the work of Bruyere et al. three meta-analyses and reviews met the study 
requirements. [TOWHEED et al. 2005, VLAD et al. 2007, REGINSTER 2007] In all of 
them, a significant improvement in pain and also in joint function was found. However, 
heterogeneity  was  high  among  the  trials  included.  [BRUYERE  et  al.  2008]  In  almost  
every  older  trial  a  daily  dose  of  500  mg  has  been  administered.  In  more  actual  trials  
doses of 1500 mg/day are administered. [TOWHEED et al. 2005]  
 
A meta-analysis of Wandel et al. included ten trials incorporating 3.803 patients with 
knee or hip OA. The group found no clinical relevant effects with glucosamine 
(800 - 1500 mg/d) or with glucosamine in combination with chondroitin on joint pain. 
There was also no effect on the joint space narrowing compared with placebo. 
[WANDEL et al. 2010] 
 
Lee at al. reported in their meta-analysis on structural efficacies of glucosamine sulfate 
and chondroitin on knee OA, that glucosamine sulfate in long-term daily treatment over 
at least 3 years has small to moderate protective effects on minimum joint space 
narrowing. [LEE et al. 2010] 
 
However, a general recommendation is not possible, since heterogeneity among 
glucosamine sulfate trials does not allow definitive conclusions or recommendations 
about  efficacy  of  glucosamine  sulfate  in  the  treatment  of  OA  or  pain  related  joint  
disorders in general. [VLAD et al. 2007] 
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8.1.2 Chondroitin sulfate 
 
Chondroitin sulfate, a natural compound of the body, structurally made of a chain of 
alternating amino sugars containing sulfuric acid, is a so-called sulfated 
glycosaminoglycan and therefore, as well as glucosamine sulfate, part of the side chains 
of proteoglycans. Chondroitin sulfate as a proteoglycan is a major intracellular 
component of connective tissue, cartilage and skeleton. [THE AMERICAL 
HERITAGE® SCIENCE DICTIONARY 2005] The ULS for chondroitin sulfate is 
1200 mg/d. [HATHCOCK and SHAO 2006] In Europe chondroitin sulfate is declared 
as a dietary supplement and available over the counter. [BLACK et al. 2009] 
 
Hochberg reported in his meta-analysis that an oral daily dose of 800 mg chondroitin 
sulfate appears to have a small but significant effect on slowing the rate of joint space 
narrowing over a period of 2 years in patients with symptomatic radiographic knee OA. 
[HOCHBERG 2010] 
 
Reichenbach et al. reported in a meta-analysis (total of 3846 patients, duration up to 132 
weeks) a small effect of chondroitin sulfate (800 – 1200 mg/d) on symptoms of 
osteoarthritic disorders such as pain. [REICHENBACH et al. 2007] 
 
Lee at al. reported in their meta-analysis, that chondroitin sulfate may delay the natural 
radiological progression of knee OA. Long-term daily treatment, over at least 2 years 
with a daily oral intake of 800 mg, may retard degeneration of cartilage affecting the 
knee. [LEE et al. 2010] 
 
8.1.3 Collagen hydrolysate 
 
Collagens are the most prevalent proteins in human organism and are responsible for 
mechanical stability of tissue and organs. All of the 20 different collagen types have the 
typical triple helix in common. This structure is responsible for the high stability of 
collagen. [LÖFFLER 2004] 
Collagen hydrolysate is the enzymatic hydrolyzed form of collagen. Such as collagen 
type II, the main characteristics of collagen hydrolysate are the amino acids proline and 
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glycine which are responsible for stability and regeneration of cartilage. [HENROTIN et 
al. 2011] 
 
In the randomized, double-blind, controlled multicenter trial of Benito-Ruiz et al., 250 
subjects with primary OA of the knee were given collagen hydrolysate (10 g/d) as a 
dietary supplement over a period of six month. There was a significant improvement in 
knee joint comfort. [BENITO-RUIZ et al. 2009] 
 
In the RCT of Zuckley et al., 190 patients with mild symptoms of knee OA were given 
300 mg collagen hydrolysate per day as a dietary supplement over a period of 14 weeks. 
Results show a significant improvement of certain strength and work performance tests; 
that means an improvement of knee functional mobility. [ZUCKLEY et al. 2004] 
 
A recent RCT by Bruyere et at. examined the effect of collagen hydrolysate in articular 
pain. A treatment with 1200 mg collagen hydrolysate per day over a period of 6 month 
showed significant improvement in joint pain. [BRUYERE et al. 2012] 
 
8.2 Vitamins and Antioxidants 
 
Vitamins  are  essential  nutrients  and  must  be  obtained  from the  diet.  From a  chemical  
point of view vitamins are structurally not related and have different functions in human 
body. Some vitamins have no upper level of intake, because of their low bioavailability 
and fast metabolism at high doses of intake. Some vitamins have pharmacologic or 
toxic potential at higher intake. Vitamin A and D for example could have lethal dosages 
at very high intake, but overdoses with the daily diet are unlikely.  
Vitamin needs are individually different and depend on factors such as age, gender, 
health status etc. They are part of this chapter due to their role in radical metabolism. 
Free radicals can lead to destruction of macromolecules, and as a consequence to so-
called oxidative stress, if the body is not able to inactivate them. Endogenous sources of 
free radicals are the arachidonic acid cascade (AA-cascade), inflammation, 
phagocytosis, respiratory chain or physical activity.  
The body comprises of an effective non-enzymatic and enzymatic defense system. Non-
enzymatic defense is performed by antioxidants, among them also vitamins. They have 
either individual antioxidant potential, but can also act as synergist by regenerating 
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primary antioxidants. Therefore, vitamin supplements are often administered as 
supplement-complex. For example vitamin C is able to enhance the antioxidant effect of 
vitamin E since vitamin C regenerates the active form of vitamin E. Also vitamin E and 
selenium is a synergistic couple with antioxidant potential. [ELMADFA and 
LEITZMANN 2004] 
 
8.2.1 Vitamin D 
 
Vitamin D can be synthesized in the human organism in case of enough ultraviolet B 
(UVB) radiation (exposure of the sun),  and therefore,  in definition,  vitamin D is not a 
“real” vitamin. Vitamin D represents a pro-hormone, and a precursor for the hormone 
calcitriol. There are two forms of fat soluble vitamin D, also called calciferol, in human 
diet. One is cholecalciferol (vitamin D3), which is from animals and synthesized in the 
skin, and the second form is the plant derived ergocalciferol (vitamin D2). The potential 
for synthesizing vitamin D3 in skin decreases with age. [ELMADFA and LEITZMANN 
2004, DGE et al. 2012] 
 
Nutrients containing vitamin D in relevant doses are fish-liver, fish oil, fatty fish, egg 
yolk and some edible mushrooms. Milk and milk products contain vitamin D, but only 
in very low doses. In some regions vitamin D enrichment of food (e.g. margarine or 
milk) is a way of protecting against vitamin deficiency. [ELMADFA and LEITZMANN 
2004, DGE et al. 2012] 
 
Functions of Vitamin D 
 
? increases calcium absorption 
? regulation of gen-transcription (function as steroid-hormone) with the 
consequence of increased intestinal absorption of calcium absorption 
? bone formation and degradation 
? controls cell proliferation in skin 
[ELMADFA and LEITZMANN 2004] 
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Recommended daily intake: 20 µg in case of non-endogenous synthesizes. The average 
intake with normal food is only 2-3 µg/day. Therefore, differences must be 
compensated with endogenous synthesize or dietary supplements. [DGE et al. 2012] 
 
Three observational studies in humans have been performed in the last 10 years 
[BERGINK et al. 2009, BREIJAWI et al. 2009, FELSON et al. 2007]. The serum level 
of 25-hydroxyvitamin D was reported. One study showed no association between serum 
level and structural joint degradation [FELSON et al. 2007]. Whereas, in the other two 
studies a correlation between low vitamin D serum level and joint degradation was 
observed. [BERGINK et al 2009, BREIJAWI et al. 2009] Therefore, further studies are 
required to investigate if there is an association between vitamin D intake and 
osteoarthritic disorders, or not. 
 
8.2.2 Antioxidants 
 
Antioxidants prevent other substances from the undesired effect of oxidation. In their 
capacity as radical scavenger antioxidants have a high physiological importance. In the 
human organism they inactivate reactive oxygen species (ROS), which lead to oxidative 
stress in high doses. Oxidative stress itself is one of the reasons for the aging process, 
and is also one major aim in the development of chronic diseases. ROS have been 
associated with the inflammation process of several diseases including rheumatoid 
arthritis and OA. [CANTER et al. 2007] 
In a review by Canter et al. the antioxidant potential of the vitamins A, C, E and 
selenium and their role in the treatment of arthritis (inflammatory arthritis and OA) was 
critically discussed. Twenty randomized clinical trials were considered, but the quality 
of the studies was generally poor because most of the included studies did not 
adequately describe the study design and statistical analyses. However, the conclusion 
of the review was missing evidence that vitamins A, C and selenium have any effect in 
the treatment of arthritis. The results for vitamin E were contradictory. [CANTER et al. 
2007] 
 
A review by Brien et al. included six studies concerning OA and the nutritional 
supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM). Both 
supplements have antioxidant potential, possible actions are slowing down or stopping 
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leakage from injured cells, stabilizing cell membranes or scavenging hydroxyl radicals 
which trigger inflammation.  
Due to the poor methodology of the included DMSO studies no final conclusion can be 
drawn for any effects of this supplement. Data from MSM studies on the other hand are 
more rigorous and there is moderate positive but not clear evidence that MSM is more 
effective than placebos in the treatment of knee OA. Therefore further studies are 
mandatory, also to identify optimal dosage and long-term safety. [BRIEN et al. 2008] 
 
8.2.3 Rosehip powder 
 
Rosehips are the pseudo fruits of Rosa Canina, commonly known as dog rose. Rosa 
Canina is a wild rose species native in Europe, Northwest Africa and Western Asia. 
Rosehips are known for their high vitamin C levels (500mg/100g) which is the highest 
in middle European fruits. Rosehips puree has 20 times more vitamin C compared to 
lemons. Additionally, the fruits are rich in provitamin A, B-vitamins, minerals and the 
trace elements copper and zinc.  
The raw fruits of Rosa Canina are not suitable for consumption. Therefore, dried fruits 
as powder, tea, syrup, jam are the most common products. [BIELENBERGER 2007] 
 
Standardized hip powder and antioxidant and anti-inflammatory effects have been 
evaluated in several trials.  
A review by Christensen et al. comprised only three randomized controlled trials 
(RCTs) with 287 patients over a small period of 3 month of low quality, so the results 
should be taken with care. They concluded that a small to moderate short-term efficacy 
of preparations with Rosa Canina hip powder (5 g/d), with a small but clinically 
relevant reduction of pain in OA patients was possible. Further long-term studies are 
needed to confirm the results of this review. [CHRISTENSEN et al. 2008] 
 
A One-Year-Survey (77 patients out of 296 completed the survey) by Chrubasik et al. of 
moderate quality (no representative sample, no control group, no defined dose/day) 
suggested a positive effect of rosehip and seed powder (Litozin®) on patients with 
chronic pain as well as unspecific low back pain and osteoarthritic pain. [CHRUBASIK 
et al. 2008] A review by Chrubasik et al. in 2008 could not assure the anti-inflammatory 
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and anti-oxidative effects of Rosa Canina with clinical significance. Therefore further 
research is needed. [CHRUBASIK et al. 2008] 
 
8.3 Phytochemicals 
 
Phytochemicals are physiologically active plant components of different chemical 
structure. To date approximately 100.000 different phytochemicals have been identified, 
and 5.000 to 10.000 are present in the human diet. [DGE 2010] 
Due to their chemical structure and function phytochemicals can be classified into 
 
1. Polyphenols 
2. Carotenoids 
3. Phytoestrogens 
4. Glucosinolates 
5. Sulfides 
6. Monoterpenes 
7. Saponines 
8. Protease-Inhibitors 
9. Phytosterols 
10. Lectins 
 
Phytochemicals are part of the daily diet in fruits, vegetables, legumes, nuts, as well as 
whole grain products and fermented foods. In plants, phytochemicals have several 
responsibilities, for example protecting the plant from predators or microbes, growth 
regulation and some of them are plant pigments. Phytochemicals are not established as 
essential nutrients, but in their function as bioactive substances they could have 
biological significance in human metabolism. [DGE 2010]  
 
Phytochemicals are discussed to have anti-oxidative, anti-carcinogenic, immune-
modulating, anti-microbial, anti-thrombotic, anti-inflammatory, blood pressure 
regulating, cholesterol level reducing, and blood-glucose level regulating and digestion-
furthering potential. [ELMADFA and LEITZMANN 2004]  
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Recommendations for daily intake of phytochemicals are not reasonable because of the 
lack  of  scientific  data.  It  is  possible  that  some of  these  nutrients  develop  their  special  
effects only in synergism with others. Therefore, the German Nutrition Society (DGE) 
recommends a high consumption of fruits and vegetables to ensure a sufficient supply 
of phytochemicals. [DGE 2010] 
 
8.3.1 Avocado-soybean unsaponifiables 
 
Avocado and soybean unsaponifiables (ASU) are phytochemicals. ASU is an extract of 
oils generally mixed in the ratio one-third avocado oil and two-thirds soybean oil. Main 
components of ASU are ȕ-sitosterol, campesterol and stigmasterol which are 
phytosterols. 
The underlying premise is that this ASU-mixtures stimulates the synthesis of aggrecan 
and extracellular matrix components such as type II collagen (collagen is a natural 
component of tendons, joints, ligaments and muscles) because of their positive effects 
on  human chondrocytes.  ASU is  discussed  to  reduce  the  production  and  the  action  of  
inflammatory substances and reduces the production of catabolic mediators. Thus, ASU 
could prevent cartilage degradation and support the repair of damaged cartilage. 
[AMEYE and CHEE 2006, ARC 2009, HENROTIN et al. 2011] Henrotin et al. 
reported positive effects of ASU (300 mg/d up to 2 years) on joint space loss, NSAID 
intake, pain and joint function. [HENROTIN et al. 2011] 
The conclusion of the meta-analysis of randomized controlled trials of Christensen et al. 
is that ASU (300 mg/d over an average trial duration of 6 month) are neither worse nor 
better than other medications for treating OA in knee and hip. There is no evidence of 
significant negative side effects. There are better chances of success in patients with 
knee OA than in patients with hip OA. [CHRISTENSEN et al. 2008] 
 
8.4 Lipids 
 
The term lipid includes a variety of different molecules with similar chemical and 
physical properties. From the chemical point of view a classification into lipids with FA 
as structural component and so called lipid-like substances, which are isoprene 
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derivates. The majority of natural fats consist of triglycerides, which are esters of 
glycerin with long chain FA, and traces of mono- and diglycerides, free FA, 
phospholipids and non-saponifiable components. [ELMADFA and LEITZMANN 2004] 
 
Classification of natural fats and oils with relevance in human diet 
 
? simple lipids (neutral fats, waxes) 
? complex lipids (phospholipids, glycolipids, lipoproteins) 
? fat-derivates/fat-soluble substances (FA, glycerin, sterols, fat-soluble vitamins, 
lipochromes, antioxidants, flavors) [ELMADFA and LEITZMANN 2004] 
 
Biological functions of lipids 
 
Structural  function: lipids are present in all  cells  of the body, especially in the cells of 
the  nervous  system.  They  are  essential  parts  of  the  cell  membrane  as  well  as  the  
membrane of cell organelles such as mitochondria and lysosomes.  
 
Energy support: lipids supplies humans and plant organism with energy, and are 
responsible for long-term reserves. 1 g fat provides 37.7 kJ.  
 
Body functions: unsaturated long-chain FAs are essential for brain and retina. 
 
Immune  function:  one  of  the  most  important  functions  of  lipids  is  their  function  as  
precursor for the biosynthesis of eicosanoids. 
 
Thermal insulation: fats below the skin protect against body heat loss. 
 
Protective function: simple lipids protect inner organs against mechanical influences. 
 
Carrier of fat-soluble vitamins, flavors and odorous substances: lipids are essential for 
the bioavailability of lipid-soluble agents. 
[ELMADFA and LEITZMANN 2004, LÖFFLER 2004] 
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8.4.1 Fatty acids 
 
Fatty acids (FAs) consist of a hydrocarbon chain and a carboxyl group. In most cases 
FAs contain an even number of C-atoms and in some cases one or more double bonds. 
[LÖFFLER 2004] 
 
Main characteristics of FAs are chain length, degree of saturation and localization of the 
double bonds. 
 
Chain length 
FAs with up to 4 C-atoms are defined as short-chain, with 6-12 C-atoms as medium-
chain and with more than 12 C-atoms as long-chain FAs.  
 
Degree of saturation 
Saturated FAs have no double-bond in the molecule, mono-unsaturated FAs have one 
double-bond and PUFA shave more than one double-bond in the molecule.  
 
Localization of double bonds 
Furthermore a classification by the localization of the first double-bond from the methyl 
end is possible. n-3 FAs have their first double-bond at the third C-atom, n-6 FAs at the 
sixth C-atom and n-9 fatty acids at the ninth C-atom. Finally a differentiation into 
cis-FA and trans-FAs is possible. In cis-configuration adjacent hydrogen atoms are on 
the same side of the double bond and in trans-configuration hydrogen atoms are on 
opposite sides of the double bond [ELMADFA and LEITZMANN 2004, LÖFFLER 
2004] 
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Nomenclature 
 
Both, trivial names and chemical designations are used in literature.  
 
Saturated FAs 
 
Palmitic acid – Hexadecanoic acid – C16H32O2 – C16:0 
 
 
Stearic acid – Octadecanoic acid – C18H36O2 – C18:0 
Figure 7: Saturated FAs 
 
Unsaturated FAs 
 
 
Palmitoleic acid – cis-9-Hexadecenoic acid – C16H30O2 – C16:1n-7 
 
 
Oleic acid – cis-9-Octadecenoic acid – C18H34O2 – C18:1n-9 
Figure 8: Unsaturated FAs  
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PUFAs 
 
 
Linoleic acid – cis-9,12-Octadecadienic acid – C18H32O2 – C18:2n6 
 
 
Alpha-linolenic acid (ALA) – cis-9,12,15-Octadecatrienic acid – C18H30O2 – C18:3n3 
 
 
Arachidonic acid (AA) – cis-5,8,11,14-Eicosatetraenoic acid – C20H32O2 – C20:4n-6 
 
 
Eicosapentanoic acid (EPA) – cis-5,8,11,14,17-Eicosapentanoic acid – C20H30O2 – C20:5n-3 
 
 
Docosahexaenoic acid (DHA) - cis-4,7,10,13,16,19-Docosahexaenoic acid – C22H32O2 - C22:6n-3 
Figure9: PUFAs 
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8.4.1.1 Essential fatty acids 
 
N-3 and n-6 FAs belong to PUFAs. PUFAs contain two or more double bonds. The 
classification whether n-3 or n-6 depends, as explained above, on the location of the last 
double bond relative to the terminal methyl end of the molecule. The human organism is 
not  able  to  synthesize  the  two  fatty  acids  linoleic  acid  and  ALA.  Therefore  these  so  
called  essential  FAs  must  be  obtained  from the  diet.  Any other  n-3  or  n-6  FA can  be  
derived from those two essential FAs. [LÖFFLER 2004] 
 
PUFAs are essential parts of all cell membranes due to their influence on membrane 
fluidity and their functions as membrane-bound enzymes and receptors. PUFAs are 
regulators of a broad range of functions in the body, including blood pressure, blood 
clotting, and optimal brain and nervous system development and function. [WALL et al. 
2010] 
 
n-3 and n-6 FAs play an important role in the initiation and regulation of inflammatory 
mediators and can influence them significantly. [GOLDBERG and KATZ 2007] 
 
These PUFAs are the precursors for the inflammatory mediators termed eicosanoids 
(prostaglandine, prostacycline, thromboxane, leukotriene). [WALL et al. 2010, 
LÖFFLER 2004] 
  
8.4.1.2 Biosynthesis of eicosanoids 
 
Linoleic acid, supplied from food, is the precursor for AA in the human body and is 
formed via several intermediates and inserting of double bonds by enzymes (elongase 
and desaturase). AA itself is the precursor for the prostaglandins of series 2, 
thromboxane of series 2, leukotriene of series 4, resolvin and the lipoxines. Further 
biosynthesis leads to docosapentaenoic acid. In human organism the ALA is the 
precursor  for  the  biosynthesis  of  EPA,  which  is  the  initial  substance  to  synthesize  
prostaglandins of series 3, thromboxane of series 3, leucotrienes of series 5, resolvins 
and the lipoxines. DHA is a product of further biosynthesis and the precursor for 
resolvins and neuroprotectins. [WALL et al. 2010] 
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The series 2 prostaglandins are defined as pro-inflammatory, the prostaglandins of 
series 3 as anti-inflammatory, due to their potential of reducing inflammatory mediators 
such as IL-1Į, COX-2, 5-lipoxygenase and its activator FLAP (five lipoxygenase 
activating protein), as well as catabolic factors (metalloproteinase MMP or ADAMTS). 
[AUSMAN 2006, AMEYE 2006] 
 
8.4.1.3 Requirements 
 
The recommended dietary intake for adults for linoleic acid is 100 mg/kg normal 
weight/day on average. That means approximately 6.5 g linoleic acid/day or 2.5 % of 
the daily needed energy. 
For ALA a daily intake of approximately 1 g, 0.5 % of daily needed energy respectively 
is recommended. Accordingly the n-6 to n-3 ratio is preferably 5:1. [ELMADFA and 
LEITZMANN 2004, DGE 2012] 
Due  to  the  numerous  positive  effects  of  n-3  fatty  acids  EPA  and  DHA  a  therapeutic  
intervention with high amounts of purified n-3 FA could be possible. Regularly 
consumption of fish (1-2 times a week) could have a preventive effect. [ELMADFA and 
LEITZMANN 2004, DGE 2012] 
 
Dietary sources of n-3 FA 
 
EPA and DHA are mainly present in fish oil from fatty fish such as menhaden, herring, 
sardine, sprat, and in liver oil from fish and wale. In plant oils like linseed oil, soybean 
oil, flax oil, as well as in nuts and dark green leafy vegetables high amounts of ALA are 
found. [ÖGE 2012, EBERMANN and ELMADFA 2008]  
 
Dietary sources of n-6 FA 
 
Oils obtained from sunflower, thistle, pumpkin seed, corn germ and grape seed are rich 
in linoleic acid. Animal source food such as meat, butter, milk and milk products and 
egg yolk contain high amounts of AA. [ÖGE 2012] 
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8.4.1.4 PUFAs and health effects 
 
Since years PUFAs are of special interest regarding cardiovascular diseases, cancer, 
mental health and degenerative disorders. In the following the most important and most 
discussed diseases will be explained. 
 
8.4.1.4.1 Cardiovascular diseases 
 
In a review by Delgado-Lista et al. the effects of marine omega-3 PUFAs on subjects 
with high cardiovascular risk have been evaluated. A reduction of cardiovascular events 
of 10 %, cardiac death of 9 % and coronary events of 18 % is possible when 
administered marine n-3 PUFAs as food or in supplements for at least 6 month. There is 
also a trend for lower total mortality compared to control groups. The included studies 
are highly heterogenic regarding dosages, and therefore not easy to compare. 
[DELGADO-LISTA et al. 2012]  
The German Nutrition Society summarized the results of more than 100 studies of 
different evidence classes including RCTs, intervention, cohort and case control studies. 
According to the resulting fat-guidelines the efficacy of ALA in the primary and 
secondary  prevention  of  coronary  heart  diseases  is  possible.  Primary  prevention  of  
cardiovascular diseases through higher intake of PUFAs is also possible. There is high 
evidence for lower mortality in case of increased intake of fish, fish oil and n-3 FAs. 
Secondary prevention of coronary heart diseases by PUFA supplementation is of 
insufficient evidence. [DGE 2006] 
 
8.4.1.4.2 Cancer 
 
The latest review of epidemiological studies of Gerber in 2012 evaluated that 
Į-linolenic  acid  is  neither  a  risk  nor  a  protecting  factor  of  different  types  of  cancers.  
There is limited evidence for a possible role of n-3 PUFAs in cancer prevention 
concerning colorectal, prostate and breast cancers due to insufficient homogeneity of the 
different studies [GERBER 2012]. Results of the latest RCT by Murphy et al. reported a 
positive role of n-3 PUFAs as adjuvant in lung cancer patients. Fish oil supplementation 
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may increase chemotherapy efficacy without affecting treatment toxicity (e.g. nausea, 
vomiting). [MURPHY et al. 2011]  
The German Nutrition Society reviewed more than 90 studies with different study 
designs (cohort, case control and intervention studies) could not find any relation 
between PUFA intake and cancer risk. An increased intake of long chain n-3 FAs (EPA 
and DHA) can possibly lower the risk of colon cancer. [DGE 2006] 
 
8.4.1.4.3 Metabolic syndrome 
 
A recent review by Lopez-Huertas showed that the supplementation with n-3 PUFAs of 
>1 g/day for at least 3 months leads to a significant reduction (7 – 25 %) of triglycerides 
confirming a hypotriglyceridemic effect of n-3 PUFAs. [LOPEZ-HUERTAS 2012] In 
the fat-guidelines of the German Nutrition Society the hypotriglyceridemic effect of n-3 
PUFAS is also reported (25 % in healthy people and 34 % in hyperglyceridemic 
patients). [DGE 2006] The potential of n-3 FAs to reduce triglyceride concentration is 
related to their effects on reducing hepatic production and secretion of VLDL, their 
positive effects on plasma lipolytic activity and the stimulation of ȕ-oxidation of FAs in 
the liver. [JACOBSEN 2008] Lopez-Huertas associates, that this hypotriglyceridemic 
effect may lead to reduced small dense low density lipoprotein (LDL) particles and 
therefore maybe to lower inflammation processes in metabolic syndrome patients. 
However, no clear effects were found on other metabolic syndrome markers such as 
high blood pressure, increased risk for coronary heart diseases, insulin resistance and 
glucose intolerance and typ-2 diabetes as a consequence. [LOPEZ-HUERTAS 2012] 
8.4.1.4.4 Osteoporosis 
 
Orchard et al. reviewed the impact of n-3 FAs on osteoporosis. Three included RCTs of 
the past 10 years showed significantly positive effects of a n-3 FA mixture combined 
with calcium, n-3 FA fortified dairy products and a high ALA diet on bone related 
osteoporosis marker [GRIEL et al. 2007, MARTIN-BAUTISTA et al. 2010, 
DAWCZYNSKI et al. 2009]. Whereas four of the included RCTs found no significant 
effects regarding n-3 FA intervention. [SALARI et al. 2010, CORNISH and 
CHILIBECK 2009, DODIN et al. 2005, APPLETON 2011] Due to the small number of 
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RCTs and the heterogeneity of the published studies, recommendations for n-3 FA 
supplementation for skeletal health are not needed at the moment. [ORCHARD 2012] 
 
8.4.1.4.5 Fish Oil and Perna Canaliculus (green-lipped mussel) 
 
Fish  and  fish  oil  is  rich  in  PUFAs.  As  shown  previously  PUFAs  are  precursors  for  
inflammatory mediators and therefore are crucially involved in the process of 
inflammatory diseases. [WALL et al. 2010] 
 
In the 1990s the influence of Perna Canaliculus on arthritic diseases was of increased 
interest, since Maoris with a high and frequent consumption of green-lipped mussels 
had a significantly reduced risk for arthritic diseases. Therefore, a stabilized powder of 
green-lipped mussel was produced and marketed.  
Green-lipped mussel extracts contain concentrated n-3 FA such as EPA and DHA. 
[BRIEN 2008] As explained above n-3 FAs show anti-inflammatory activity by 
inhibiting membrane AA metabolism, and at the same time synthesizes of pro-
inflammatory prostaglandins (PGE2) from AA is reduced. 
[BRIEN 2008, WANN 2010, EFTHIMIOU and KUKAR 2010] 
 
A  review  by  Henrotin  et  al.  reported  effects  of  n-3  FAs  on  OA.  Only  two  clinical  
studies of low [CHO et al. 2003] to moderate [STAMMERS et al. 1992] quality could 
be found, therefore a definitive conclusion is not possible. A treatment with the New-
Zealand green-lipped mussel extract (200 mg/d over a period of 8 weeks) improved 
symptoms including pain and joint function. [CHO et al. 2003] A treatment with cod 
liver oil (10 ml/day for 24 weeks) as an adjutant to NSAIDs did not show any effects on 
pain and joint function. [STAMMERS et al. 1992] 
 
The results of the meta-analysis of Goldberg and Katz (17 studies with 823 patients 
included), where n-3 PUFA supplementation in patients with rheumatoid arthritis or 
joint pain has been reviewed, suggest that EPA/DHA supplementation for 3 – 4 month 
reduces joint pain intensity, morning stiffness, number of painful and/or tender joints, 
and NSAID consumption. The author’s conclusion is that n-3 PUFA supplementation is 
an attractive adjunctive treatment for joint pain, but further studies in humans are 
required. [GOLDBERG and KATZ 2007] 
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In their RCT Dawczynski et al. examined the influences of n-3 PUFAs and gamma-
linolenic  (GLA)  acid  on  disease  activity  in  patients  with  rheumatoid  arthritis.  60  
participating patients in four test groups received PUFAs (3g/d), GLA (3.2g/d), a 
combination of both (1.6g PUFAs/d and 1.8g GLA/d) or olive oil (3g/day) over a period 
of 12 month. Intake of n-3 PUFAs or GLA led to an increased incorporation of EPA and 
DHA in plasma lipids and cell suggesting a possible positive effect in the treatment of 
chronic inflammatory diseases such as rheumatoid arthritis. [DAWCZYNSKI ET AL. 
2011]  Adam  et  al.  reported  in  their  RCT  a  positive  effect  of  a  diet  low  in  AA  (<  90  
mg/d) and the intake of fish oil capsules (30 mg/kg body weight). Significant 
improvement in tender and swollen joints, as well as enrichment of EFA in erythrocyte 
lipids and lower formation of prostaglandin metabolites has been results of the 8 month 
trial including 68 patients with rheumatoid arthritis. [ADAM et al. 2003] Galarraga et 
al. demonstrated in their RCT of 9 moth duration that oral supplements of 10 g cod 
liver/day (containing 2.2 g EPA and DHA) reduces the daily intake of NSAIDs in 39 % 
of the patients with rheumatoid arthritis without any negative effects on their disease 
activity.  [GALARRAGA et  al.  2008]  Berbert  et  al.  figured  out,  that  a  daily  treatment  
with 3 g fish oil n-3 FAs in combination with olive oil significantly improves joint pain, 
hand grip strength and morning stiffness in patients with rheumatoid arthritis. Although 
the trial was of parallel randomized design there were only 34 patients involved. 
Therefore results should be taken with care. [BERBERT et al. 2005] 
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9 Critical Review - Protocol 
 
The  review  protocol  follows  the  principle  of  the  Preferred  Reporting  Items  for  
Systematic reviews and Meta-Analyses (PRISMA) statement.  
[LIBERATI 2009, MOHER 2009] 
 
JOURNAL 
The Journal of Nutrition 
 
TITLE 
The Role of Omega-3 Fatty Acids in Shoulder Joint Disorders – A Critical Review 
 
AUTHORS 
Brenda Laky1, MSc, PhD; Maria-Theres Hamedl2; Karl-Heinz Wagner2, PhD; Philipp 
Heuerer1, MD; Ulrich Lanz1, MD; Werner Anderl1, MD. 
1 Department of Orthopedics, St. Vincent Hospital, Vienna, Austria 
2Department of Nutritional Sciences, The University of Vienna, Austria 
 
INTRODUCTION 
The introduction will give an overview of n-3 PUFAs and their role in health and 
disease.  Since  patients  with  inflammatory  joint  diseases  may  benefit  from  n-3  FAs,  
special focus will be placed on shoulder joint disorders. Background information will be 
obtained from other chapters of the diploma thesis.  
 
AIM 
The main objective of the critical review will be an overview of the current knowledge 
of n-3 PUFAs in shoulder disorders including OA and RC pathologies. A specific aim 
of the review will be an investigation regarding the potential effects of n-3 PUFAs 
supplementation on the treatment or as a treatment adjuvant of shoulder pathologies. 
 
METHODS 
Scientific relevant studies will be identified using systematic searches of electronic 
databases of Medline (PubMed), ExcerptaMedica Database (Embase), and Cochrane 
Registry of Controlled Trials (CENTRAL) and manual searches from January 1990 to 
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May 2012. The manual search will include abstracts presented at meetings, ongoing 
clinical trials (www.clinicaltrials.gov), reference lists, and reviews on the topic to 
identify eligible trials. The search strategy will involve combining specific terms related 
to n-3 PUFAs AND specific shoulder joint disorders including terms relating to OA OR 
RC pathologies. Medical Subject Headings (MeSH) will be used wherever possible.  
 
STUDY SELECTION 
The search will be performed according to the following predefined criteria: (1) only 
scientific publications with FAs related terms linked to either OA or RC pathologies; (2) 
only studies on human adults; (3) all study designs; and (4) only publications in English 
or German will be considered. All studies not meeting inclusion criteria will be 
excluded from the review. 
 
STUDY CHARACTERISTICS 
The following study characteristics will be extracted: (a) publication details (e.g. first 
author); (b) quality criteria of study design (e.g. level of evidence); (c) study 
participants details (e.g. age, gender); (d) shoulder pathology details; (e) primary 
outcome variable(s)(e.g.  n-3  PUFA supplement  and  risk  of  RC retears);  (f)  secondary  
outcome variable(s): e.g. inflammation related parameters; (g) reported confounding 
factors (e.g. co morbidities, funding sources) 
 
Two  independent  reviewers  (MTH  and  BL)  will  perform  all  aspects  of  the  search  
strategy including article search, examination of the abstracts for relevance, assessment 
of inclusion criteria and review the full text articles in detail as indicated. All collected 
data will be recorded and compared; disagreement will be resolved via mutual 
consensus, and thereafter summarized. The review protocol will not be registered; 
however it will follow the principle of the Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) statement. [LIBERATI 2009, MOHER 2009] 
 
RESULTS 
Bibliographic search results: The role of n-3 FA in shoulder joint disorders 
Bibliographic search results: The role of n-3 FA in OA 
Bibliographic search results: The role of n-3 FA in RC disorders and tendon related 
disorders 
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DISCUSSION 
The main findings including the strength of evidence for each main outcome will be 
summarized. A general interpretation of the results in the context of other evidence will 
be provided. Limitations of the critical review and outcome level will be discussed. The 
conclusion will include the main outcome result and implications for future research 
will be given. 
 
REFERENCES 
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Oct;62:e1-34. 
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10 Conclusion 
The main objective of the present diploma thesis was to evaluate and critically examine 
associations between selected nutritional compounds and their impact on joint disorders. 
Osteoarthritis  (OA)  and  ways  of  alternative  intervention  are  well  discussed  in  the  
scientific literature. Especially glucosamine and chondroitin as natural occurring parts 
of the cartilage are of high interest concerning cartilage repair further reduction of pain 
and related medication. Literature research allows no definitive recommendation neither 
for glucosamine nor chondroitin. Collagen seams to influence cartilage but also here no 
recommendation is possible. Studies concerning the influence of vitamins and 
antioxidants on joint disorders are of low quality and therefore results should be taken 
with care. To better define their influence on inflammatory processes in human 
organism, further research is recommended. The role of vitamin D in bone metabolism 
and therefore in osteoporosis is already known, but is also discussed against cartilage 
disorder like OA, and interesting for rheumatoid arthritis (RC) disorders. Further 
research is necessary to investigate whether a low serum vitamin D concentration 
correlates with cartilage disorders and if supplementation with vitamin D is of interest 
in treating OA and RC disorders.  
The antioxidant and anti-inflammatory effect of rosehip powder is also discussed in 
several short term studies of different quality, which might be also of interest for 
cartilage related joint disorders. But long term studies of high quality are necessary to 
clarify relevant effects of rosehip powder on OA and RC disorders. 
Avocado-soybean unsaponifiables (ASU) are under discussion in treating cartilage 
related joint disorders since ASU stimulates the synthesis of aggrecan and extracellular 
matrix components such as collagen (collagen is a natural component of tendons, joints, 
ligaments and muscles) due to their positive effects on chondrocytes. Further, ASU 
show anti-inflammatory potential. Therefore ASU are discussed to prevent cartilage 
degradation and support the repair of damaged cartilage. However, literature shows no 
positive effect of ASU on joint disorders, but further studies could be of interest to test 
the anti-inflammatory effect of ASU on joint disorders.  
n-3 FAs and their health potential in general are well discussed in literature. Research 
showed that n-3 FAs are involved in several diseases with inflammatory background. 
Therefore, n-3 FA should be of high interest in the prevention and treatment of OA and 
RC disorders. Due to the fact that shoulder disorders are a common orthopedic problem, 
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nutritional intervention associated with weight loss could be of interest  in this kind of 
disease as well. 
Therefore, a critical review focusing on potential effects of n-3 PUFAs in shoulder 
disorders  especially  in  OA  and  RC  pathologies  will  be  a  next  step.  A  protocol  for  a  
critical review investigating the potential effects of n-3 PUFAs supplementation on the 
treatment or as a treatment adjuvant of shoulder pathologies was established and is part 
of this diploma thesis. 
 
In general, the daily diet should be considered in the treatment of OA and RC. NSAIDs 
and corticosteroids are the common way in treating joint diseases but additional 
supplementation or a diet high in nutrients can lead to a reduced medication and 
therefore higher quality of life. But further research is necessary to determine positive 
effects of the discussed nutritional components.  
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11 Summary 
Joint disorders are frequent problems involving cartilage as well as muscles, tendons, 
and ligaments, rather than bones; and often cause significant pain and dysfunction. Non-
operative medical treatment is aimed to reduce pain and inflammation and include 
pharmacological approaches such as corticosteroids and non-steroidal anti-
inflammatory  drugs  (NSAIDs).  Due  to  negative  side  effects  of  such  a  medication,  
permanent treatment is not recommendable. Non-pharmacological approaches such as 
lifestyle changes including a healthy diet may be an alternative and additional way to 
reduce symptoms and slow down progression of joint diseases. 
The main objective of this diploma thesis was to investigate whether there are positive 
effects of selected nutrients on joint disorders or not.  
Joint disorders with a possible link to dietary compounds are explained. A literature 
research focusing the nutritional components glucosamine, chondroitin, collagen, 
vitamins and antioxidants, avocado and soybean unsaponifiables, rosehip powder and n-
3 fatty acids and their effects on joints disorders has been conducted using the data 
bases PubMed and SCOPUS. Several reviews, on low and high quality studies, showed 
that recommendations or conclusions are neither possible for glucosamine nor for 
chondroitin. Collagen seams to influence cartilage but also here data are not convincing. 
Also further studies are needed to clarify if low serum vitamin D correlates with 
cartilage disorders and if supplementation with vitamin D might be of interest in 
treating OA and RC disorders. Literature research showed also no significant protection 
of joint disorders by ASU. Rosehip powder is also under discussion, but possible anti-
inflammatory effects need confirmation. Published data showed that n-3 FAs are 
involved in several diseases with inflammatory background. Therefore, n-3 FA are of 
high interest in the treatment of OA and RC disorders since they show anti-
inflammatory activity by inhibiting membrane AA metabolism, and at the same time 
synthesizes of pro-inflammatory prostaglandins from AA is reduced.. In general, diet is 
an important factor in treating OA and RC. NSAIDs and corticosteroids are the 
common  way  in  treating  joint  diseases  but  an  additional  dietary  support  with  specific  
nutrients could lead to reduced medication and increased quality of life, due to fewer 
side effects caused by NSAID and corticosteroid intake over a long treating period.  
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12 Zusammenfassung 
 
Gelenkserkrankungen sind häufig auftretende gesundheitliche Probleme welche sowohl 
Knorpel als auch Muskeln, Sehen und Bänder, weniger jedoch die Knochen betreffen 
und oft starke Schmerzen und Bewegungseinschränkungen hervorrufen. Medikamente 
wie nichtsteroidale Antirheumatika und Corticosteroide werden zur Linderung der 
Schmerzen und zur Entzündungshemmung eingesetzt. Aufgrund der Nebenwirkungen 
dieser Medikamente ist eine Langzeittherapie nicht empfehlenswert. 
Nichtpharmazeutische Behandlungsmöglichkeiten wie eine Lebensstiländerung, 
(inklusive eine gesunde Ernährung) könnte eine Alternative zur Reduktion der 
Symptome und einer Verlangsamung des Krankheitsverlaufs von Gelenkserkrankungen 
sein.  
Ziel der vorliegenden Arbeit war herauszufinden, ob ein Zusammenhang zwischen 
ausgewählten Nahrungskomponenten und Gelenkserkrankungen besteht. 
Im ersten Teil der Arbeit wurden Gelenkserkrankungen die möglicherweise mit der 
Ernährung beeinflusst werden könnten erläutert. Eine Literatursuche mittels SCOPUS 
und PubMed spezialisiert auf die Nahrungsbestandteile Glucosamin, Chondroitin, 
Kollagen, Vitamine und Antioxidantien, die unverseifbaren Bestandteile aus Avocado- 
und Sojabohnen Öl, Hagebutten und Omega-3 Fettsäuren und deren Effekte auf 
Gelenkserkrankungen wurde durchgeführt. Die dabei gefunden Reviews, welche 
Studien von sehr unterschiedlicher wissenschaftlicher Qualität enthalten, erlauben 
folgende Aussagen. Weder für Glucosamin noch für Chondroitin sind definitive 
Empfehlungen zur Supplementierung möglich.  
Kollagen scheint die Knorpelzusammensetzung zu beeinflussen, eine Empfehlung ist 
aber auch hier nicht zu geben. Weiter Studien sind auch in Bezug auf Vitamin D nötig 
um herauszufinden, ob niedriges Serum Vitamin D mit Knorpelschäden in 
Zusammenhang steht und ob Vitamin D deshalb in der Behandlung von Osteoarthritis 
und Rotatorenmanschetten-Rupturen eingesetzt werden könnte. Auch für den Einsatz 
von unverseifbaren Bestandteile aus Avocado- und Sojabohnen Öl (ASU) ergab die 
Literatursuche keinen definitiven Beweis. Das Pulver aus Hagebutten wurde in den 
letzten Jahren sehr häufig untersucht. Aber auch das entzündungshemmende Potential 
der Hagebutte muss noch weiter erforscht werden.  
Die Literatursuche ergab, dass n-3 Fettsäuren an einigen Erkrankungen mit 
Entzündungshintergrund beteiligt sind. Deshalb sollten n-3 Fettsäuren auch in der 
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Behandlung von Osteoarthritis und Rotatorenmanschetten-Rupturen vermehrt in 
Betracht gezogen werden.  
Zusammengefasst könnte die Ernährung eine alternative zusätzliche 
Behandlungsmöglichkeit im Falle von Osteoarthritis und Rotatorenmanschetten-
Rupturen sein. Um die Einnahme von nichtsteroidalen Antirheumatika und 
Corticosteroiden zu verringern könnte eine Supplementierung mit zuvor genannten 
Nahrungsbestandteilen in Erwägung gezogen werden, bzw. zusätzlich zur 
medikamentösen Therapie eingesetzt werden. Eine verringerte Einnahme dieser 
Medikamente würde in weiterer Folge zu einer höheren Lebensqualität führen, da die 
Nebenwirkungen durch die Langzeiteinnahme reduziert werden könnten. 
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